nach oben

Tumor Biology

Erschienen in:

01.06.2013 | Research Article

The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells

verfasst von: Yang Liu, Liang Wang, Xu-Yong Lin, Jian Wang, Juan-Han Yu, Yuan Miao, En-Hua Wang

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The objective of the current study was to investigate the expression pattern and clinicopathological significance of differentiated embryo–chondrocyte-expressed gene 1 (DEC1) in patients with non-small-cell lung cancer (NSCLC). In 118 archived NSCLC tissues, the positive rate of DEC1 was reduced in human lung cancer samples (36/118, 30.5 %) compared with adjacent normal lung tissues (106/118, 89.8 %), as measured by immunohistochemical staining. Loss of DEC1 was correlated with poor differentiation (p = 0.005) and high p-TNM stage (p = 0.002). Consistently, downregulation of DEC1 by siRNA knockdown promoted the growth and colony formation in the A549 lung cancer cell line, and overexpression of DEC1 inhibited the growth and colony formation in the BE1 lung cancer cell line. In addition, a significant negative correlation was found between DEC1 and cyclin D1 (p = 0.014) in 118 cases of NSCLC. Knockdown of DEC1 resulted in the upregulation of cyclin D1, and overexpression of DEC1 led to the downregulation of cyclin D1. Together with the observation that DEC1 bound directly to the promoter region of cyclin D1 in A549 cells, these results indicate that loss of DEC1 may promote tumor progression in NSCLC through upregulation of cyclin D1, and DEC1 might serve as a novel therapeutic target of NSCLC.

Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.PubMedCrossRef

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ 1995;311:899–909

O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:9022–8.CrossRef

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef

Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–44.PubMedCrossRef

Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006;66:9736–43.PubMedCrossRef

Boudjelal M, Taneja R, Matsubara S, Bouillet P, Dolle P, Chambon P. Overexpression of stra13, a novel retinoic acid-inducible gene of the basic helix–loop–helix family, inhibits mesodermal and promotes neuronal differentiation of p19 cells. Genes Dev. 1997;11:2052–65.PubMedCrossRef

Shen M, Kawamoto T, Yan W, Nakamasu K, Tamagami M, Koyano Y, et al. Molecular characterization of the novel basic helix–loop–helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem Biophys Res Commun. 1997;236:294–8.PubMedCrossRef

Guillaumond F, Lacoche S, Dulong S, Grechez-Cassiau A, Filipski E, Li XM, et al. Altered STRA13 and DEC2 circadian gene expression in hypoxic cells. Biochem Biophys Res Commun. 2008;369:1184–9.PubMedCrossRef

10.

Qian Y, Zhang J, Yan B, Chen X. Dec1, a basic helix–loop–helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem. 2008;283:2896–905.PubMedCrossRef

11.

Yamada K, Miyamoto K. Basic helix–loop–helix transcription factors, bhlhb2 and bhlhb3; their gene expressions are regulated by multiple extracellular stimuli. Frontiers in bioscience. A J virtual Libr. 2005;10:3151–71.CrossRef

12.

Ivanova A, Liao SY, Lerman MI, Ivanov S, Stanbridge EJ. Stra13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker. J Med Genet. 2005;42:565–76.PubMedCrossRef

13.

Turley H, Wykoff CC, Troup S, Watson PH, Gatter KC, Harris AL. The hypoxia-regulated transcription factor dec1 (stra13, sharp-2) and its expression in human tissues and tumours. J Pathol. 2004;203:808–13.PubMedCrossRef

14.

Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, et al. The transcription factor dec1 (stra13, sharp2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br J Cancer. 2004;91:954–8.PubMedCrossRef

15.

Zheng Y, Jia Y, Wang Y, Wang M, Li B, Shi X, et al. The hypoxia-regulated transcription factor dec1 (stra13, sharp-2) and its expression in gastric cancer. Omics A J Genet Biol. 2009;13:301–6.CrossRef

16.

Li Y, Zhang H, Xie M, Hu M, Ge S, Yang D, et al. Abundant expression of dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem J. 2002;367:413–22.PubMedCrossRef

17.

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Wykoff CC, Gatter KC, et al. Dec1 (stra13) protein expression relates to hypoxia-inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003;200:222–8.PubMedCrossRef

18.

Shi XH, Zheng Y, Sun Q, Cui J, Liu QH, Qu F, et al. Dec1 nuclear expression: a marker of differentiation grade in hepatocellular carcinoma. World J Gastroenterol. 2011;17:2037–43.PubMedCrossRef

19.

Wang W, Reiser-Erkan C, Michalski CW, Raggi MC, Quan L, Yupei Z, et al. Hypoxia inducible bhlhb2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2010;401:422–8.PubMedCrossRef

20.

Shi X, Zheng Y, Ma W, Wang Y. Possible involvement of DEC1 on the adverse effects of quinolone antibiotics. Toxicology. 2010;271:1–4.PubMedCrossRef

21.

Bhawal UK, Sato F, Arakawa Y, Fujimoto K, Kawamoto T, Tanimoto K, et al. Basic helix–loop–helix transcription factor dec1 negatively regulates cyclin d1. J Pathol. 2011;224:420–9.PubMedCrossRef

22.

Zhang L, Li QQ. Embryo-chondrocyte expressed gene 1, downregulating hypoxia-inducible factor 1alpha, is another marker of lung tumor hypoxia. Acta Pharmacol Sin. 2007;28:549–58.PubMedCrossRef

23.

Wu Y, Sato F, Yamada T, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada K, Abiko Y, Kato Y, Kijima H: The bhlh transcription factor dec1 plays an important role in the epithelial–mesenchymal transition of pancreatic cancer. International Journal of Oncology 2012

24.

Harbour JW, Dean DC. The rb/e2f pathway: expanding roles and emerging paradigms. Genes Dev. 2000;14:2393–409.PubMedCrossRef

25.

Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–30.PubMedCrossRef

26.

Malumbres M, Barbacid M. Cell cycle, CDKS and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.PubMedCrossRef

27.

Blain SW. Switching cyclin d-cdk4 kinase activity on and off. Cell Cycle. 2008;7:892–8.PubMedCrossRef

28.

Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Imaizumi T, Imanaka T, et al. Basic-helix-loop-helix (bhlh) transcription factor dec2 negatively regulates vascular endothelial growth factor expression. Genes Cells: Devoted Molecular Cellular Mech. 2008;13:131–44.CrossRef

29.

Xu Q, Ma P, Hu C, Chen L, Xue L, Wang Z, et al. Overexpression of the dec1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. PLoS One. 2012;7:e41862.PubMedCrossRef

30.

Ming J, Jiang G, Zhang Q, Qiu X, Wang E. Interleukin-7 up-regulates cyclin d1 via activator protein-1 to promote proliferation of cell in lung cancer. Cancer Immunol Immunother. 2012;61:79–88.PubMedCrossRef

31.

Kim JK, Diehl JA. Nuclear cyclin d1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292–6.PubMedCrossRef

32.

Rossner MJ, Dorr J, Gass P, Schwab MH, Nave KA. Sharps: mammalian enhancer-of-split- and hairy-related proteins coupled to neuronal stimulation. Mol Cell Neurosci. 1997;10:460–75.PubMedCrossRef

33.

Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. Regulation of stra13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the ubc9/ubiquitin proteasome degradation pathway. J Biol Chem. 2001;276:15306–15.PubMedCrossRef

34.

Sun H, Lu B, Li RQ, Flavell RA, Taneja R. Defective t cell activation and autoimmune disorder in stra13-deficient mice. Nat Immunol. 2001;2:1040–7.PubMedCrossRef

35.

Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition of PPAR gamma 2 gene expression by the hif-1-regulated gene dec1/stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell. 2002;2:331–41.PubMedCrossRef

36.

Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350:512–5.PubMedCrossRef

37.

Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, et al. Transcriptional regulation of the cyclin d1 promoter by stat5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999;18:1367–77.PubMedCrossRef

Titel: The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells
verfasst von: Yang Liu
Liang Wang
Xu-Yong Lin
Jian Wang
Juan-Han Yu
Yuan Miao
En-Hua Wang
Publikationsdatum: 01.06.2013
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0697-z

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma

Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer

Altered expression of SIRT gene family in head and neck squamous cell carcinoma

Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma

Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma

Glutathione S-transferase T1 null genotype is associated with oral cancer susceptibility in Asian populations

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie